For your hydroalcoholic solution needs

SEQENS produces up to 75,000L of hydroalcoholic solution per day.

A main actor in Pharmaceutical Synthesis and Specialty Ingredients

Two main business activities supported by R&D expertise and global assets

A leader in pharmaceutical synthesis

Offering a wide range of technologies, Seqens provide its clients custom manufacturing services as well as a large portfolio of APIs & intermediates. We offer our customers with an access to our network of 3 R&D centers, 4 pilot units and 12 cGMP manufacturing sites and 6 cGMP multi-purposes sites to ensure a smooth in-house scale-up from early clinical phases to the commercial stage.

Discover

Cross-functional knowledge in specialty ingredients

Seqens offers a wide continuum of technologies covering small-scale to large-scale chemical synthesis and distillation including distinctive reactions such as Fiedel-Craft, Grignard and low-metal capabilities. This industrial network is supported by focused R&D capabilities. Seqens offers high purity oxygenated solvents leveraging its back-integrationl and a large range of Minerals Specialties produced.

Discover

A large expertise
in cosmetics

Seqens has built a wide, comprehensive and cutting edge offer for the cosmetic market sourced in pharmaceutics and fine chemistry know-hows.

Discover

A continuum of technologies

Seqens operates 24 industrial plants and 3 R&D centers in Europe, North America and Asia.

More than 300 scientists, engineers and experts develop tailor-made solutions for its customers and ensure that products are successfully transferred into production.

Newsroom

#Live

General

The Seqens CDMO site from Lahr reaches the Gold - EcoVadis level.

The Seqens CDMO team is pleased to announce that its manufacturing site located in Lahr (Germany) has achieved the “Gold” level following the…
General / Products & Technologies / Protéus

What flow chemistry and biocatalysis bring to synthesize a typical small molecule candidate against Covid-19 epidemic

Efficient and safe process design combining SEQENS technical capabilities: Brilacidin as a case study As already mentioned in our previous article (“Seqens…
General / Press Release

COVID - 19 LATEST UPDATES

SEQENS mobilizes its innovation to support the unprecedented research on the covid-19 and prepares its unique industrial network for anti-virus production, for…

Seqens global presence

Use interactive map
0

Employees

0

Scientists, experts and engineers

0

Manufacturing sites

0

Customers in more than 80 countries